JESÚS FERNANDO
SAN MIGUEL IZQUIERDO
Investigador en el periodo 1986-2013
Emory University
Atlanta, Estados UnidosPublicaciones en colaboración con investigadores/as de Emory University (21)
2022
-
Teclistamab in Relapsed or Refractory Multiple Myeloma
New England Journal of Medicine, Vol. 387, Núm. 6, pp. 495-505
2021
-
Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO)
Haematologica, Vol. 106, Núm. 6, pp. 1725-1732
2020
-
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study
Blood Cancer Journal, Vol. 10, Núm. 9
2019
-
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial
The Lancet Haematology, Vol. 6, Núm. 9, pp. e448-e458
-
Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma
Blood, Vol. 134, Núm. 8, pp. 668-677
2018
2017
-
A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma
British Journal of Haematology, Vol. 178, Núm. 4, pp. 547-560
2015
-
Elotuzumab therapy for relapsed or refractory multiple myeloma
New England Journal of Medicine, Vol. 373, Núm. 7, pp. 621-631
2014
-
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation
Journal of Clinical Oncology, Vol. 32, Núm. 6, pp. 587-600
2013
-
Induction therapy for newly diagnosed multiple myeloma
JNCCN Journal of the National Comprehensive Cancer Network, Vol. 11, Núm. 1, pp. 19-28
2010
-
Monoclonal gammopathy of undetermined significance: A consensus statement: Guideline
British Journal of Haematology, Vol. 150, Núm. 1, pp. 28-38
2009
-
International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)
Leukemia, Vol. 23, Núm. 10, pp. 1904-1912
-
Panobinostat and Lenalidomide Combination Phase I Trial in Myeloma
CLINICAL LYMPHOMA & MYELOMA
-
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: Impact of a dose-modification guideline
British Journal of Haematology, Vol. 144, Núm. 6, pp. 895-903
-
The research mission in myeloma
Leukemia
2008
-
Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma
British Journal of Haematology, Vol. 143, Núm. 2, pp. 222-229
-
Efficacy and safety of bortezomib in patients with renal impairment: Results from the APEX phase 3 study
Leukemia, Vol. 22, Núm. 4, pp. 842-849
-
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
Leukemia, Vol. 22, Núm. 2, pp. 414-423
2007
-
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: Final time-to-event results of the APEX trial
Blood, Vol. 110, Núm. 10, pp. 3557-3560
-
Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma
British Journal of Haematology, Vol. 137, Núm. 5, pp. 429-435